Inter-individual Variability of Coumarin 7-hydroxylation (CYP2A6 activity) in an Iranian Population

Document Type : Original Article

Authors

1 Drug research center, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, 91775-1365, Iran

2 Medical Toxicology Research Centre, Faculty of Medicine and Department of Pharmacodynamy and Toxicology, Faculty of Pharmacy, Mashhad University

Keywords

References

Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic
human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20:342-349.
2. Schneider E, Clark DS. Cytochrome P450 (CYP) enzymes and the development of CYP biosensors. Biosens Bioelectron 2013; 39:1-13.
 
3. Singh D, Kashyap A, Ram Vinay Pandey RV, Saini KS. Novel advances in cytochrome P450 research. Drug Discov Today 2011; 16:793-799.
 
4. Le Gal A, Dreano Y, Lucas D, Berthou F. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine. Toxicol Lett 2003; 144:77-91.
 
5. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA, Wolf CR. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J 1990; 267:365–371.
 
6. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29:1322-1329.
 
7. Koskela S, Hakkola J, Hukkanen J, Pelkonen O, Sorri M, Saranen A,
 
 
et al
. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 1999; 57:1407-1413.
8. Oscarson M. Genetic polymorphisms in the cytochrome p450 2a6 (cyp2a6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 2001; 29:91-95.
 
9. Lake BG. Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food Chem Toxicol 1999; 37:423-453.
 
10. Thornes D, Daly L, Lynch G, Browne H, Tanner A, Keane F
 
 
, et al.
Prevention of early recurrence of high risk malignant melanoma by coumarin. Irish Melanoma Group. Eur J Surg Oncol 1989; 15:431-435.
11. Dexeus FH, Logothetis CJ, Sella A, Fitz K, Amato R, Reuben JM,
 
 
et al.
Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. J Clin Oncol 1990; 8:325-329.
12. Gal A, Dre´ano Y,Lucas D, Berthou F. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine. Toxicol Lett 2003; 144:77-91.
 
13. Higashi E, Nakajima M, Katoh M, Tokudome S, Yokoi T. Inhibitory effects of neurotransmitters and steroids on human CYP2A6. Drug Metab Dispos 2007; 35:508-514.
 
14. Xu C, Goodz S, Sellers EM, Tyndale RF. CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 2002; 54:1245–1256.
 
15. Kim D, Wu ZL, Guengerich FP. Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis. J Biol Chem 2005; 280:40319-40327.
 
16. Pelkonen O, Rautio A, Raunio H, Pasanen M. CYP2A6: a human coumarin 7-hydroxylase. Toxicology 2000; 144:139–147.
 
17. Rautio A, Kraul H, Kojo A, Salmela E, Pelkonen O. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 1992; 2:227-233.
 
18. Rauma AL, Rautio A, Pasanen M, Pelkonen O, Torronen R, Mykkanen H. Coumarin 7-hydroxylation in long-term adherents of a strict uncooked vegan diet. Eur J Clin Pharmacol 1996; 50:133-137.
 
19. Ritschel WA, Brady ME, Tan HS, Hoffmann KA, Yiu IM, Grummich KW. Pharmacokinetics of coumarin and its 7-hydroxy-metabolites upon intravenous and peroral administration of coumarin in man. Eur J Clin Pharmacol 1977; 12:457-461.
 
20. Emamghoreishi M, Bokaee HR, Keshavarz M, Ghaderi A, Tyndale RF. CYP2A6 Allele Frequencies in an Iranian population. Arch Iran Med 2008; 11:613 – 617.
 
21. Iscan M, Rostami H, Iscan M, Guray T, Pelkonen O, Rautio A. Interindividual variability of coumarin 7-hydroxylation in a Turkish population. Eur J Clin Pharmacol 1994; 47: 315-318.
 
22. Xu P, Huang SL, Xu RH, Han XM, Zhou HH. Phenotypic polymorphism of CYP2A6 activity in a Chinese population. Eur J Clin Pharmacol 2002; 58:333-337.
 
23. Afshar M, Rouini M, Ala S. Dextromethorphan metabolic phenotyping in an Iranian population. Eur J Clin Pharmacol 2005; 60:849-854.
 
24. Kouhi H, Hamzeiy H, Bara J, Asadi M, Omidi Y. Frequency of five important CYP2D6 alleles within an Iranian population (Eastern Azerbaijan). Gnet Test Mol Biomarkers 2009; 13:665-670.
 
 

Files

Share

How to cite

Statistics